Three days. That is the distance between now and the opening of the most important oncology meeting of the year. Revolution Medicines’ plenary session on Saturday May 31 is the headline, but ASCO is far bigger than one presentation. The conference will feature data across ADCs (following two approvals in two weeks: Enhertu in early breast cancer, Datroway in first-line TNBC), next-generation checkpoint inhibitor strategies (after Regeneron’s fianlimab miss reset expectations for the LAG-3 class), cell therapy updates, and emerging modalities including bispecific antibodies and radiopharmaceuticals. Truist projects a daraxonrasib approval by end of Q3 under the CNPV program. We will provide daily coverage of the most significant data throughout the conference. Separately, we owe our readers a catch-up on a story we missed last week. AstraZeneca’s Baxfendy (baxdrostat) was approved on May 18 as the first new mechanism of action in hypertension in two decades. It inhibits aldosterone synthase, addressing the hormonal root cause of resistant blood pressure rather than the downstream symptoms. AstraZeneca expects more than $5 billion in peak annual sales. The 23 million U.S. patients with uncontrolled hypertension despite two or more medications represent the addressable population.
Catch-Up: AstraZeneca’s Baxfendy Approved as First New Hypertension Mechanism in Two Decades
What Happened: The FDA approved AstraZeneca’s Baxfendy (baxdrostat) on May 18 as the first and only aldosterone synthase inhibitor approved for the treatment of hypertension in combination with other antihypertensive medications. The approval was based on the BaxHTN Phase 3 trial, published in the New England Journal of Medicine, which showed Baxfendy 2 mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) in patients with uncontrolled or resistant hypertension on two or more medications.
Why This Is a Bigger Story Than We Initially Covered
We did not cover this approval in the daily email last week—an oversight we are correcting now. Baxfendy is not an incremental improvement to an existing drug class. It is the first genuinely new mechanism of action in hypertension in approximately twenty years. Every existing blood pressure medication—ACE inhibitors, ARBs, calcium channel blockers, diuretics, beta-blockers—works downstream of aldosterone, managing the consequences of excess aldosterone rather than preventing its production. Baxfendy works upstream, inhibiting the enzyme (aldosterone synthase) that produces aldosterone in the first place.
AstraZeneca EVP Ruud Dobber said the population of patients with uncontrolled hypertension despite multiple medications “has seen little therapeutic progress for the past two decades.” BaxHTN investigator Dr. Bryan Williams of University College London said doctors “have been waiting for an innovative medication like Baxfendy for hypertension for many years.”
The Commercial Opportunity
Approximately 23 million patients in the U.S. have uncontrolled hypertension despite being on two or more medications. These are patients for whom existing therapies are insufficient—they take multiple drugs and still cannot achieve blood pressure control. For this population, a drug that addresses the root hormonal cause rather than adding another downstream mechanism represents a genuinely different treatment approach.
AstraZeneca expects Baxfendy to generate more than $5 billion in peak annual sales. The company acquired Baxfendy’s developer, CinCor Pharma, for $1.8 billion in 2023 at a 121% premium. The drug is also being studied in chronic kidney disease and heart failure, with trials enrolling more than 20,000 patients globally. If these additional indications succeed, the commercial opportunity extends well beyond hypertension into the broader cardiorenal market.
Epidemiological data cited by AstraZeneca indicate that a 10 mmHg decrease in systolic blood pressure is associated with roughly 20% lower risk of serious cardiovascular events. Baxfendy’s 9.8 mmHg placebo-adjusted reduction puts it in the range of clinically meaningful cardiovascular risk reduction—the kind of data that supports both physician adoption and formulary coverage.
The Competition: Lorundrostat Is Coming
AstraZeneca has first-mover advantage, but it will not have the market to itself for long. Mineralys Therapeutics is developing lorundrostat, a rival aldosterone synthase inhibitor currently under FDA review with a PDUFA date in December 2026. If approved, the resistant hypertension market will split between two ASIs. AstraZeneca’s deeper commercial infrastructure and seven-month head start give it a meaningful advantage in physician awareness, formulary positioning, and market share establishment before a competitor arrives.
The emergence of two aldosterone synthase inhibitors validates the mechanism as a drug class rather than a single-product story. For cardiologists and internists who have been managing resistant hypertension with the same drug classes for two decades, having a new mechanism—potentially with two commercial options—reshapes the treatment paradigm entirely.
The resistant hypertension population has been chronically undertreated not because physicians lack motivation but because they lack effective tools. A patient already on three blood pressure medications who still cannot achieve control has limited options under the current treatment algorithm: add a fourth drug from an existing class, increase doses with diminishing returns and increasing side effects, or accept suboptimal blood pressure control and the cardiovascular risk that comes with it. Aldosterone synthase inhibition offers a fundamentally different pathway that can be layered on top of existing regimens.
The AstraZeneca acquisition of CinCor at a 121% premium looks increasingly prescient. At $1.8 billion, the deal will likely rank as one of the most value-creating acquisitions in AstraZeneca’s portfolio if Baxfendy reaches its $5 billion peak sales projection. The CKD and heart failure trials, with more than 20,000 patients enrolled globally, could expand the franchise well beyond hypertension into the broader cardiorenal market—a space where AstraZeneca’s existing Farxiga franchise already provides commercial infrastructure and physician relationships.
Our Pro brief analyzes how Baxfendy and lorundrostat will split the $5B+ resistant hypertension market, what the CKD and heart failure trials mean for the franchise beyond blood pressure, and how the ASI class compares to existing add-on therapies. [Details below.]
ASCO 2026 Preview: Five Sessions Beyond Revolution
ASCO 2026 opens Thursday May 29 in Chicago and runs through June 2. Revolution Medicines’ plenary session on Saturday is the event everyone is watching. But the conference will feature hundreds of abstracts that carry commercial and clinical significance across oncology.
1. ADC Combinations in Solid Tumors
With Enhertu approved in early breast cancer (May 16) and Datroway approved in first-line TNBC (May 22), the ADC modality is at an inflection point. ASCO will feature next-generation ADC data combining with checkpoint inhibitors, tyrosine kinase inhibitors, or other targeted therapies. Gilead’s Tubulis pipeline, Merck’s Kelun-Biotech sac-TMT program, and Daiichi Sankyo’s broader ADC platform will all be represented. The question for the field is whether ADC combinations can further improve outcomes beyond what single-agent ADCs have already achieved.
2. Checkpoint Inhibitor Sequencing and Combinations
After Regeneron’s fianlimab LAG-3 miss in melanoma, the LAG-3 class is under pressure. ASCO will present data on alternative immuno-oncology combination strategies—TIGIT inhibitors, next-generation CTLA-4 approaches, and bispecific antibodies—that could replace or complement LAG-3 as the next checkpoint combination partner. BMS’s Opdualag remains the only approved LAG-3 combination, giving it the competitive benchmark that any new combination must beat.
3. Cell Therapy Real-World Evidence
CAR-T therapies (Yescarta, Carvykti, Abecma) have been on the market for several years. ASCO will present real-world outcomes data that could expand or narrow labeled indications. For Lilly, whose in vivo CAR-T thesis through Kelonia and Orna is maturing, the real-world CAR-T data provides context for how the next generation of cell therapy might perform outside controlled clinical trials.
4. The KRAS Competitive Landscape
Revolution has the plenary with daraxonrasib. But Erasca, AbbVie/Kestrel (KST-6051 pan-KRAS inhibitor), and others will present early-stage KRAS data at ASCO that define the competitive landscape around RAS-targeted therapy. The breadth and depth of the KRAS pipeline will determine whether daraxonrasib remains the dominant RAS therapy or whether competitors can differentiate on mutation selectivity, combination potential, or safety profile.
5. Radiopharmaceuticals
Novartis’s Pluvicto grew 70% in Q1 and represents one of the fastest-growing segments in oncology. New radioligand therapy data across prostate cancer and other solid tumors will be presented at ASCO. The modality is still early in its commercial development, and the data presented this week could expand the addressable tumor types and patient populations.
Revolution Medicines Plenary: Saturday May 31
The plenary presentation remains the single most anticipated event on the 2026 oncology calendar. Brian Wolpin, MD, of Dana-Farber Cancer Institute will present full Phase 3 RASolute 302 data for daraxonrasib in second-line pancreatic ductal adenocarcinoma.
We know the topline: 13.2 months median OS versus 6.7 months (HR 0.40, p<0.0001). The plenary will add PFS data (not yet disclosed), detailed subgroup analyses across RAS mutation subtypes and patient characteristics, mature survival curves showing whether the benefit is sustained over time, and comprehensive safety data.
Truist projects an FDA approval by end of Q3 2026 if Revolution files under the CNPV program. An NDA submission at or shortly after ASCO would put the 50-day Foundayo precedent in play for an August or September approval. The CNPV caveat persists: the program is operating without Commissioner Makary, and whether acting leadership maintains the same review pace remains uncertain.
For pancreatic cancer—a disease that has resisted meaningful therapeutic progress for decades—the stakes could not be higher.
Other Developments
SERB Acquires Hansa Biopharma’s Idefirix for $128M
SERB Pharmaceuticals acquired rights to Swedish firm Hansa Biopharma’s Idefirix (imlifidase) for $128 million upfront on May 24. Idefirix is an IgG-cleaving enzyme approved in the EU for desensitization treatment in highly sensitized adult kidney transplant recipients. The deal gives SERB a commercial-stage transplant medicine. For patients who cannot receive kidney transplants because their immune systems produce antibodies that would reject the organ, Idefirix offers a path to transplantation by temporarily removing those antibodies.
Section 232 Device Report: Still Pending
The Commerce Department’s Section 232 report on medical devices, originally expected in late May based on the September 2025 investigation timeline, has not yet been released. The delay creates uncertainty for the medtech sector. Medtronic, Boston Scientific, Abbott, Intuitive Surgical, and Stryker are all watching for the report’s recommendations, which will inform whether imported medical devices face a tariff framework similar to the pharmaceutical Section 232 structure.
The delay is notable because the pharmaceutical tariff framework has been in effect since April, and medtech companies have been operating without clarity on whether they will face similar treatment. J.P. Morgan’s Q1 deal report showed medtech M&A at $26.6 billion across 37 deals—a pace that could accelerate or decelerate significantly depending on the report’s conclusions. If tariffs are recommended, companies with overseas manufacturing would face pressure to onshore production or absorb higher costs. If the report recommends no action, medtech avoids the supply chain restructuring that pharma has been navigating for months. Either way, the delay itself is creating a planning vacuum that affects capital allocation decisions across the device sector.
Strategic Themes
1. Baxfendy Opens a Cardiovascular Growth Cycle That Has Been Dormant for Two Decades
The cardiovascular drug market has been overshadowed by oncology and GLP-1 for years. Baxfendy’s approval as the first new hypertension mechanism in twenty years, combined with the new AHA/ACC LDL cholesterol guidelines, asundexian’s Factor XIa NDA acceptance, and BridgeBio’s ATTR-CM data, collectively signal that cardiovascular is re-emerging as a growth vertical. AstraZeneca’s $5 billion peak sales projection for a single hypertension drug would make Baxfendy one of the largest cardiovascular franchises launched this decade. The CKD and heart failure trials could extend the franchise further. For an industry that has focused its M&A and pipeline investment primarily on oncology and metabolic disease, the cardiovascular renaissance deserves renewed attention.
2. ASCO Will Set the Oncology Narrative for the Rest of 2026
The conference is not just a scientific meeting. It is where formulary positioning decisions are informed, M&A targets are identified, analyst models are revised, and clinical practice adoption is shaped. Strong Phase 2 data at ASCO historically triggers acquisition interest in the months that follow. Disappointing readouts trigger partnership restructuring. With biopharma M&A running at approximately $93 billion through April and the KRAS, ADC, and cell therapy spaces all actively consolidating, ASCO data drops this week could catalyze the next wave of deal-making.
3. The ADC Modality Has Two First-Line Approvals in Two Weeks—and ASCO Will Determine What Comes Next
Enhertu in early breast cancer. Datroway in first-line TNBC. Both from the AstraZeneca/Daiichi Sankyo partnership. The ADC pipeline presentations at ASCO will signal which tumor types and treatment settings are next for front-line ADC expansion. Lung cancer, colorectal cancer, and gastric cancer are the most likely candidates. Each expansion moves ADCs further up the treatment algorithm, where patient populations are larger and the commercial opportunity is greater.
4. Three Days Out, the Revolution Plenary Carries the Weight of an Entire Disease
Pancreatic cancer has a five-year survival rate below 15%. It is the third leading cause of cancer death in the United States. Second-line treatment has historically offered months, not years, of additional survival. Daraxonrasib’s topline data—13.2 months versus 6.7 months—suggests a doubling of survival in the second line. If the full data at the plenary confirm this benefit across subgroups with an acceptable safety profile, it will be the most significant advance against pancreatic cancer in the disease’s history. Saturday cannot come fast enough.
Frequently Asked Questions
What is Baxfendy?
AstraZeneca’s baxdrostat, the first aldosterone synthase inhibitor approved for hypertension. Approved May 18. Lowers systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) in patients on two or more medications. AstraZeneca projects $5B+ peak sales. Mineralys Therapeutics’ lorundrostat is a rival with a December PDUFA date.
Why is Baxfendy significant?
It is the first genuinely new mechanism of action in hypertension in approximately twenty years. All existing blood pressure drugs work downstream of aldosterone. Baxfendy inhibits the enzyme that produces aldosterone, addressing the root hormonal cause of resistant hypertension.
When does ASCO start?
Thursday May 29 through June 2 in Chicago. Revolution Medicines plenary session Saturday May 31. Brian Wolpin of Dana-Farber presenting full Phase 3 RASolute 302 data.
What do we already know about Revolution’s data?
Topline: 13.2 months median OS versus 6.7 months (HR 0.40) in second-line pancreatic cancer. The plenary will add PFS data, subgroup analyses, mature survival curves, and detailed safety data. Truist projects Q3 2026 approval under CNPV.
What is lorundrostat?
Mineralys Therapeutics’ rival aldosterone synthase inhibitor under FDA review with a December 2026 PDUFA date. If approved, the resistant hypertension market would have two ASI options. AstraZeneca has a seven-month first-mover advantage with Baxfendy.
What is the SERB/Hansa deal?
SERB acquired rights to Idefirix (imlifidase) for $128M upfront. The drug is an IgG-cleaving enzyme approved in the EU for desensitization in highly sensitized kidney transplant recipients.
Where is the Section 232 device report?
Still pending. Originally expected late May. The delay creates uncertainty for medtech companies awaiting tariff framework details for imported medical devices.
What else should I watch at ASCO?
Beyond Revolution: ADC combination data across tumor types, checkpoint inhibitor strategies after the LAG-3 miss, cell therapy real-world evidence, KRAS competitive landscape presentations, and radiopharmaceutical data from Novartis and emerging programs.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Baxfendy vs. Lorundrostat. We analyze how two aldosterone synthase inhibitors will split the $5B+ resistant hypertension market, what AstraZeneca’s first-mover advantage means for physician adoption and formulary positioning, and how the CKD and heart failure trials could extend the franchise beyond blood pressure.
ASCO Deep Preview. We provide a session-by-session guide to the five most commercially significant data presentations beyond Revolution, identify the abstracts most likely to trigger M&A interest or analyst model revisions, and assess the capital markets positioning heading into the conference.
ADC Label Expansion Tracker. We compile Enhertu (early breast cancer) and Datroway (first-line TNBC) into a modality-level analysis of what first-line ADC approvals mean for the next wave of filings across lung, colorectal, and gastric cancers.
Plus: Revolution plenary data requirements, Section 232 device report delay analysis, SERB/Hansa transplant deal, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
